Here are three insights:
1. Novadaq Technologies develops fluorescent imaging technology for blood flow visualization in vessels and tissue perfusion related to cardiac, cardiovascular, gastrointestinal, plastic, microsurgical and reconstructive procedures.
2. The transaction is expected to be dilutive to Stryker’s 2017 adjusted net earnings per diluted share by $0.03 to $0.05.
3. In the agreement, Stryker paid $11.75 per share, with a net purchasing price of $654 million and nearly $47 million cash, totaling approximately $701 million.
More articles on devices and implants:
Global surgical navigation systems market to see 6.5% CAGR: 4 takeaways
Medtronic makes $40M third tranche investment in Mazor earlier than expected: 10 things to know
MicroPort Orthopedics launches Procotyl Prime Acetabular Cup System: 5 highlights
